Esmolol to Treat the Hemodynamic Effects of Septic Shock: A Randomized Controlled Trial.

ABSTRACT:

Introduction

Septic shock is often characterized by tachycardia and a hyperdynamic hemodynamic profile. Use of the beta antagonist esmolol has been proposed as a therapy to lower heart rate, thereby improving diastolic filling time and improving cardiac output, resulting in a reduction in vasopressor support.

Methods

We conducted a two-center, open-label, randomized, Phase II trial comparing esmolol to placebo in septic shock patients with tachycardia. The primary endpoint was improvement in hemodynamics as measured by the difference in norepinephrine equivalent dose (NED) between groups at 6 hours after initiation of study drug. Secondary outcomes included assessing differences in inflammatory biomarkers and oxygen consumption (VO2).

Results

A total of 1,122 patients

SUBMITTER: Cocchi MN 

PROVIDER: S-EPMC10448435 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature